About this Research Topic
The immune system harbors great potential for controling and eliminating tumors. Recent developments in the field of immuno-oncology has led to unprecedented clinical benefits for a broad spectrum of solid tumors. The overall aim is to (i) reprogram the suppressive tumor microenvironment (TME), (ii) promote anti-tumor antigen presentation, (iii) eliminate regulatory T-cells, and (iv) ultimately engage cytotoxic T-cells and activated innate immune cells such as macrophages.
Immunotherapy (IT) approaches currently have several challenging limitations including (i) low response rate; (ii) development of resistance and (iii) causing severe immune-related adverse effects (IrAEs), which underline the importance of adequate patient selection. Importantly, IT holds promising synergistic potential when combined with chemotherapy and anti-angiogenic therapy (AAT) as part of multi-modal oncologic treatment regimes. Recent evidence suggests that radiotherapy (RT) in particular may possess strong immune-stimulatory effects which could be clinically relevant for boosting the efficacy of immunotherapy. Studies have shown that RT can (i) increase tumor antigen release and (ii) enhance antigen presentation that is able to trigger a systemic anti-tumor immune response which can be of potential clinical relevance. In selected patients that harbor rather passive immune-surveillance and less immunogenic (“cold”) tumors, and thus do not sufficiently respond to IT alone, the combination of RT with IT could help to convert these tumors to being highly immunogenic (“hot”). Interestingly, AAT also seems to promote the development of a tumoricidal immune microenvironment by (i) directly facilitating immune cell infiltration and (ii) alleviating hypoxia-induced immunosuppression in the tumor microenvironment. Collectively, published data suggest that there is a synergistic link between RT and AAT, which ultimately could help potentiate the response to IT. However, the complex interactions between RT and IT and/or AAT remain poorly understood. Many research questions including optimal timing, scheduling and dosing, as well as patient selection and side effects of combined therapy approaches, remain to be addressed.
This Research Topic aims to give a comprehensive overview of the current field with particular emphasis on the future outlook of RT and AAT as complementary approaches to improve IT in solid tumors. We welcome the submission of Review, Mini-Review, Original Research and Opinion articles that cover the following topics:
(i) The interplay between the vascular system and the immune system in cancer.
(ii) Synergistic effects of AAT and RT on IT and the potential impact on IrAE.
(iii) The role and contributions of both the innate and adaptive immune system with specific focus on the immunosuppressive microenvironment and its therapeutic relevance.
(iv) The contribution of the myeloid compartment to tumor resistance against AAT, RT, and IT.
Submissions related to patient selection, as well as the safety and feasibility of multi-modal therapeutic regimens are highly encouraged. Submissions can include findings on clinical guidance to evaluate response prediction, need for biomarkers, and subsequent patient follow-up after combined AAT, RT, and IT approaches.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.